

HM2026-09: Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma who Have Received 1-3 Prior Lines of Therapy (Trilogy5)

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- diagnosed with multiple myeloma - have multiple myeloma that has come back or has not responded to treatment - have received at least 3 prior lines of treatment, including a proteasome inhibitor, an immunomodulatory drug (IMiD), and an anti-CD38 antibody - see the ClinicalTrials.gov listing for complete inclusion criteria

Exclusion Criteria:

- have an active hepatitis infection - have multiple myeloma that has spread to the brain or central nervous system - have certain allergies to the study medications or their ingredients - have had major surgery within the past 2 weeks, are still recovering from surgery, or have surgery planned during the study - have received or plan to receive a live vaccine within 4 weeks before starting the study or during study treatment - see the ClinicalTrials.gov listing for complete exclusion criteria

Conditions & Interventions

Conditions:

Blood Disorders, Cancer

Keywords:

Clinics and Surgery Center (CSC), blood cancer, blood disorders, MM, Multiple Myeloma

More Information

Description: The purpose of this study is to evaluate a new study drug, JNJ-79635322, in adults with multiple myeloma that has returned after treatment or has not responded to previous treatment. Participants must have received 1 to 3 prior lines of therapy, including lenalidomide and an anti-CD38 antibody. Researchers want to learn how safe the study drug is and how well it works compared with the current standard treatment for multiple myeloma.

Study Contact: Eric Homan - homa0030@umn.edu

Principal Investigator: Daniel O'Leary

Phase: PHASE3

IRB Number: STUDY00028442

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.